Lubberink, Mark

Rapid decrease in delivery of chemotherapy to tumors after anti-VEGF therapy: Implications for scheduling of anti-angiogenic drugs

Van der Veldt, A. A. M., Lubberink, M., Bahce, I., Walraven, M., de Boer, M. P., Greuter, H. N. J. M., Hendrikse, N. H., Eriksson, J., Windhorst, A. D., Postmus, P. E., et al. (2012) · Cancer Cell

Angiogenesis and VEGF in CancerCancer, Hypoxia, and Metabolism

Cited by 337

Blood–brain barrier P-glycoprotein function in Alzheimer's disease

van Assema, D. M. E., Lubberink, M., Bauer, M., van der Flier, W. M., Schuit, R. C., Windhorst, A. D., Comans, E. F. I., Hoetjes, N. J., Tolboom, N., Langer, O., et al. (2012) · Brain

Drug Transport and Resistance MechanismsAlzheimer's disease research and treatments

Cited by 318

Studies of a Next-Generation Silicon-Photomultiplier–Based Time-of-Flight PET/CT System

Hsu, D. F. C., Ilan, E., Peterson, W. T., Uribe, J., Lubberink, M., & Levin, C. S. (2017) · Journal of Nuclear Medicine

Medical Imaging Techniques and ApplicationsRadiation Detection and Scintillator Technologies

Cited by 241

Evaluation of Penalized-Likelihood Estimation Reconstruction on a Digital Time-of-Flight PET/CT Scanner for 18 F-FDG Whole-Body Examinations

Lindström, E., Sundin, A., Trampal, C., Lindsjö, L., Ilan, E., Danfors, T., Antoni, G., Sörensen, J., & Lubberink, M. (2018) · Journal of Nuclear Medicine

Medical Imaging Techniques and ApplicationsRadiation Dose and Imaging

Cited by 99

[11C]UCB-A, a novel PET tracer for synaptic vesicle protein 2A

Estrada, S., Lubberink, M., Thibblin, A., Sprycha, M., Buchanan, T., Mestdagh, N., Kenda, B., Mercier, J., Provins, L., Gillard, M., et al. (2016) · Nuclear Medicine and Biology

Radiopharmaceutical Chemistry and ApplicationsMedical Imaging Techniques and Applications

Cited by 71

Expectancy effects on serotonin and dopamine transporters during SSRI treatment of social anxiety disorder: a randomized clinical trial

Hjorth, O. R., Frick, A., Gingnell, M., Hoppe, J. M., Faria, V., Hultberg, S., Alaie, I., Månsson, K. N. T., Rosén, J., Reis, M., et al. (2021) · Translational Psychiatry

Neurotransmitter Receptor Influence on BehaviorAnxiety, Depression, Psychometrics, Treatment, Cognitive Processes

Cited by 46

Parametric Net Influx Rate Images of 68Ga-DOTATOC and 68Ga-DOTATATE: Quantitative Accuracy and Improved Image Contrast

Ilan, E., Sandström, M., Velikyan, I., Sundin, A., Eriksson, B., & Lubberink, M. (2017) · Journal of Nuclear Medicine

Medical Imaging Techniques and ApplicationsNeuroendocrine Tumor Research Advances

Cited by 34

Regularized reconstruction of digital time-of-flight 68Ga-PSMA-11 PET/CT for the detection of recurrent disease in prostate cancer patients

Lindström, E., Velikyan, I., Regula, N., Alhuseinalkhudhur, A., Sundin, A., Sörensen, J., & Lubberink, M. (2019) · Theranostics

Medical Imaging Techniques and ApplicationsProstate Cancer Diagnosis and Treatment

Cited by 32

Application of positron emission tomography in psychiatry—methodological developments and future directions

Cervenka, S., Frick, A., Bodén, R., & Lubberink, M. (2022) · Translational Psychiatry

Medical Imaging Techniques and ApplicationsNeurotransmitter Receptor Influence on Behavior

Cited by 32

Reduced serotonin synthesis and regional cerebral blood flow after anxiolytic treatment of social anxiety disorder

Frick, A., Åhs, F., Appel, L., Jonasson, M., Wahlstedt, K., Bani, M., Merlo Pich, E., Bettica, P., Långström, B., Lubberink, M., et al. (2016) · European Neuropsychopharmacology

Anxiety, Depression, Psychometrics, Treatment, Cognitive ProcessesNeurotransmitter Receptor Influence on Behavior

Cited by 22

Association between amygdala neurokinin-1 receptor availability and anxiety-related personality traits

Hoppe, J. M., Frick, A., Åhs, F., Linnman, C., Appel, L., Jonasson, M., Lubberink, M., Långström, B., Frans, Ö., von Knorring, L., et al. (2018) · Translational Psychiatry

Neuropeptides and Animal PhysiologyNeurotransmitter Receptor Influence on Behavior

Cited by 18

Serotonin and dopamine transporter availability in social anxiety disorder after combined treatment with escitalopram and cognitive-behavioral therapy

Hjorth, O., Frick, A., Gingnell, M., Engman, J., Björkstrand, J., Faria, V., Alaie, I., Carlbring, P., Andersson, G., Jonasson, M., et al. (2022) · Translational Psychiatry

Anxiety, Depression, Psychometrics, Treatment, Cognitive ProcessesNeurotransmitter Receptor Influence on Behavior

Cited by 13